Compare KKR & Co Inc (KKR) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? KKR & Co Inc trades at $86.07 (market cap $76.84B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: KKR & Co Inc is far larger — about 15.3× Travere Therapeutics Inc. Common Stock's market cap, and KKR & Co Inc pays a 0.91% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold KKR & Co Inc for 67 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| KKR | TVTX | |
|---|---|---|
Market Cap | $76.84B | $5.02B |
Volume | 12,064,615 | 2,060,842 |
Sector | Financials | Health |
52-Week High | $142.75 | $67.52 |
52-Week Low | $83.88 | $26.79 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | -$604.63M | $5.15B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR trades at $87.16, down 4.75% today, amid bearish technical signals despite strong analyst support. The stock shows mixed fundamentals with a P/E of 27.85 and recent earnings beats, though Q4 2025 missed expectations. Recent corporate activity includes strategic investments in global ventures and a $0.20 dividend declaration. Cash flow trends indicate volatile operational performance, with 2025 net cash flow at $1.78 billion.
Outlook remains cautiously optimistic given 88.9% analyst buy ratings and a $123.20 price target, representing 41% upside. Key risks include execution of recent acquisitions and market sensitivity to private equity cycles. The current dip may present a buying opportunity for long-term investors seeking exposure to alternative asset management growth.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
